Fulgent Genetics, Inc. (FLGT) Stock Was Up 4.35 Percent Today. Here’s Why.

Today’s big question for investors is, “what’s going on with Fulgent Genetics, Inc. (NASDAQ:FLGT) stock? Its price is jumping 0.73 points, trading at $17.5 levels, and is up 4.35% from its previous close of $16.77. The shares seem to have an active trading volume day with a reported 102089 contracts so far this session. FLGT shares had a relatively better volume day versus average trading capacity of 325.04 thousand shares, but with a 8.38 million float and a 0.84% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for FLGT stock indicates that the average analyst price target is $12.15 per share. This means the stock has a potential decrease of -30.57% from where the FLGT share price has been trading recently.

During the recent trading session for Fulgent Genetics, Inc. (NASDAQ:FLGT), the company witnessed their stock rise $0.77 over a week and surge $2.86 from the price 20 days ago. When compared to their established 52-week high of $17.64, the high they recorded in their recent session happens to be higher. Their established 52-week high was attained by the company on 11/02/20. The recent low of $4.25 stood for a -0.79% since 02/20/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.17 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.

Looking at the current readings for Fulgent Genetics, Inc., the two-week RSI stands at 71.45. This figure suggests that FLGT stock, for now, is oversold, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current FLGT readings is similarly very revealing as it has a stochastic reading of 86.71% at this stage. This figure means that FLGT share price today is being oversold.

Technical chart claims that Fulgent Genetics, Inc. (FLGT) would settle between $16.99/share to $17.22/share level. However, if the stock price goes below the $16.55 mark, then the market for Fulgent Genetics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $16.34 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.55. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.

Analysts at Piper Jaffray raised their recommendation on shares of FLGT from Neutral to Overweight in their opinion released on November 05. Piper Jaffray analysts have lowered their rating of Fulgent Genetics, Inc. (NASDAQ:FLGT) stock from Overweight to Neutral in a separate flash note issued to investors on March 01. Analysts at Raymond James lowered the stock to a Mkt Perform call from its previous Outperform recommendation, in a research note that dated back to November 07.

FLGT equity has an average rating of 2.5, with the figure leaning towards a bullish end. 2 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 1 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 1 analysts rated Fulgent Genetics, Inc. (NASDAQ:FLGT) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.

Moving on, FLGT stock price is currently trading at 52.9X forward 12-month Consensus EPS estimates, and its P/E ratio is 0 while for the average stock in the same group, the multiple is 49.6. Fulgent Genetics, Inc. current P/B ratio of 5.8 means it is trading at a premium against its industry’s 5.

Fulgent Genetics, Inc. (FLGT)’s current-quarter revenues are projected to climb by nearly 49.9% to hit $8.51 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 53% from $21.36 million to a noteworthy $32.67 million. At the other end of the current quarter income statement, Fulgent Genetics, Inc. is expected to see its adjusted earnings surge by roughly 500% to hit $0.04 per share. For the fiscal year, FLGT’s earnings are projected to climb by roughly 288.9% to hit $0.17 per share.